Spending on pharmaceuticals in Italy: macro constraints with local autonomy

Area of Science:

• Health Services Research
• Pharmaceutical Policy
• Public Health Administration

Background:

• Italy's national health service (SSN) is decentralizing, empowering local health enterprises (LHEs).
• Drug policy involves both central government and regional LHEs.
• Government focus has been on cost containment and cost minimization for drug reimbursement.

Purpose of the Study:

• To analyze the drug policy and spending decisions within Italy's evolving national health service.
• To examine the influence of central and local authorities on drug expenditure and reimbursement.
• To assess the strategies employed by local health enterprises to improve drug utilization by general practitioners.

Main Methods:

• Analysis of central government's role in drug expenditure, pricing, and reimbursement.
• Examination of local voluntary agreements between LHEs and general practitioners (GPs).
• Review of tools used by LHEs, including expenditure reports and clinical guidelines.

Main Results:

• Central government controls drug expenditure, pricing, and reimbursement criteria, prioritizing cost containment.
• LHEs are actively promoting better drug use through voluntary agreements and clinical guidelines.
• Tools like prescription reports and monitoring are common, but focus on health outcomes is limited.

Conclusions:

• Italy's drug policy is characterized by a strong emphasis on cost containment at both macro and micro levels.
• Local health enterprises show initiative in optimizing drug use, but a shift towards health outcomes is nascent.
• The system lacks a centralized health technology assessment body, potentially hindering efficient drug use.